GPC3 mRNA nanovaccine data
Researchers published preclinical results for an ER‑membrane‑mimetic GPC3 mRNA nanovaccine that elicited strong antitumor immunity against hepatocellular carcinoma in models. The study signals growing convergence between molecular immunotherapy and diagnostic sampling—FNA specimens may become critical for monitoring treatment response. (nature.com)
Communications Biology “Article in Press” lists Tian Zeng, Qing Gao and colleagues at the University of South China as lead authors; the manuscript was received 30 July 2025 and accepted 9 March 2026 (doi:10.1038/s42003-026-09891-6). (nature.com) The team reports a platform built from poly T–modified PLGA nanoparticles that condense a GPC3 mRNA with a modified poly(A) tail via A–T hydrogen bonding and then cloaks the particle with endoplasmic‑reticulum membrane to yield the biomimetic formulation P-(H)-m. (nature.com) In murine Hepa1‑6 tumor models the paper shows statistically smaller tumors in GPC3‑mRNA–treated animals versus OVA‑mRNA controls and immunofluorescence documented significantly higher counts of CD8+ and CD4+ tumor‑infiltrating lymphocytes in treated tumors. (nature.com) Glypican‑3 (GPC3) is consistently reported as highly prevalent in HCC—published analyses place overexpression in roughly 70–80% of hepatocellular carcinomas, supporting its selection as a tumor‑restricted antigen. (ajp.amjpathol.org)30129-9/fulltext) Historic cytology data demonstrate GPC3 immunocytochemistry on liver fine‑needle aspirates returned positive staining in 18/20 HCC FNAs (90% sensitivity) with negative staining in 20/20 metastatic and 20/20 benign aspirates in the cited series. (acsjournals.onlinelibrary.wiley.com) Vaccine‑trial methodology already uses ultrasound‑guided lymph node fine‑needle aspiration to sample draining nodes for germinal‑center and cellular immune responses at roughly 2–8 weeks post‑boost, and a current trial record specifies LN FNA at 3–6 weeks after booster doses. (hsrc.himmelfarb.gwu.edu) (clinicaltrials.gov) Protocols combining LN‑FNA with downstream immunophenotyping and single‑cell RNA or spectral flow workflows have been published for vaccine studies, indicating practical laboratory pathways to profile vaccine‑induced cellular responses from small aspirates. (sciencedirect.com)
